News/ News/ Oncology Incyte, MorphoSys’ CAR-T rival tafasitamab approved in EU Phil Taylor CAR-T therapies, EU, Incyte, MorphoSys, non-Hodgkin lymphoma, regulatory approval, tafasitamab 0 Comment Incyte and MorphoSys’ antibody therapy tafasitamab has been approved in Europe, promising to provide a more convenient alternative Share X Incyte, MorphoSys’ CAR-T rival tafasitamab approved in EU https://pharmaphorum.com/news/incyte-morphosys-car-t-rival-tafasitamab-approved-in-eu/